Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis

Arunachalam, Ashwini; Zhang, Ina; Zhao, Bin; Frederickson, Andrew M.; Pietanza, M. Catherine

doi:10.1016/j.lungcan.2023.01.003

Cited by 6 publications

(3 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, chemotherapy is one of the most important treatments available [ 3 ]. However, the efficacy of anti-tumour drugs is often influenced by their safety and resistance [ 4 , 5 ]. Many studies have demonstrated that the interaction between the tumour microenvironment (TME) and anti-tumour drugs is a critical factor in determining treatment outcomes [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Global trends in bufalin application research for cancer from 2003 to 2022: A bibliometric and visualised analysis

Tang,

Feng,

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Global trends in bufalin application research for cancer from 2003 to 2022: A bibliometric and visualised analysis

Tang,

Feng,

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Lenvatinib is a multikinase inhibitor that primarily inhibits vascular endothelial growth factor receptors 1 . In Japan, lenvatinib is approved for the treatment of unresectable or metastatic cancer 2–5 . With regard to thyroid cancer, total thyroidectomy, followed by radioactive iodine therapy, is typically performed as the initial treatment.…”

Section: Introductionmentioning

confidence: 99%

“…1 In Japan, lenvatinib is approved for the treatment of unresectable or metastatic cancer. [2][3][4][5] With regard to thyroid cancer, total thyroidectomy, followed by radioactive iodine therapy, is typically performed as the initial treatment. Pharmacotherapies, including lenvatinib, are administered as the second-line therapy.…”

Section: Introductionmentioning

confidence: 99%

Histological findings of thyroid cancer after lenvatinib therapy

Okubo,

Toda,

Sato

et al. 2023

Histopathology

View full text Add to dashboard Cite

AimsLenvatinib is a multikinase inhibitor used for treating unresectable or metastatic cancers, including thyroid cancer. As total thyroidectomy followed by radioactive iodine therapy is a commonly recommended initial treatment for thyroid cancer, histological findings of the thyroid after lenvatinib therapy remain unclear. Therefore, the aim of this study was to analyse in‐vivo changes in patients who underwent thyroidectomy after lenvatinib therapy.Methods and resultsWe screened 167 patients with thyroid cancer [papillary thyroid cancer (PTC), n = 102; follicular thyroid cancer (FTC), n = 26; anaplastic thyroid cancer (ATC), n = 39] who underwent lenvatinib therapy. Among these patients, six underwent thyroidectomy (lenvatinib‐treated group: PTC, n = 3; FTC, n = 1; ATC, n = 2), and the specimens were examined. Five patients with PTC who did not receive lenvatinib therapy were included for comparison (untreated group). Microvessel density (MVD) was evaluated in both groups. The PTC and FTC specimens showed relatively more ischaemic changes than ATC specimens. Coagulative necrosis and ischaemic changes in cancer cells were frequently observed. ATC specimens showed fibrosis and mild cell damage. As hypothyroidism is a common side effect of lenvatinib therapy, non‐cancerous thyroid tissues were also examined. Histological findings included mild lymphocytic infiltration, lymphoid follicular formation, histiocytic reaction and follicular epithelial destruction. The MVD in lenvatinib‐treated tissues was significantly lower than that in untreated tissues.ConclusionsLenvatinib therapy probably induces relatively specific ischaemic changes in thyroid cancer cells. Moreover, inflammatory cell infiltration and decreased MVD occur to varying degrees in non‐cancerous thyroid tissue and may be related to hypothyroidism, a side effect of lenvatinib.

show abstract

Effect and Mechanism of Curdione Combined with Gemcitabine on Migration and Invasion of Bladder Cancer

Chi,

Duan,

Hasan

et al. 2023

Biochem Genet

View full text Add to dashboard Cite

Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis

Cited by 6 publications

References 58 publications

Global trends in bufalin application research for cancer from 2003 to 2022: A bibliometric and visualised analysis

Global trends in bufalin application research for cancer from 2003 to 2022: A bibliometric and visualised analysis

Histological findings of thyroid cancer after lenvatinib therapy

Effect and Mechanism of Curdione Combined with Gemcitabine on Migration and Invasion of Bladder Cancer

Contact Info

Product

Resources

About